Organophosphate induced delayed polyneuropathy in man: An overview

Abstract About 80 years have passed since the first cases of organophosphate induced delayed polyneuropathy (OPIDP), as the consequence of human poisoning with certain organophosphorus compounds, were described in the literature. OPIDP is a relatively rare neurodegenerative disorder in humans charac...

Full description

Saved in:
Bibliographic Details
Published in:Clinical neurology and neurosurgery 2011-01, Vol.113 (1), p.7-10
Main Authors: JOKANOVIC, Milan, KOSANOVIC, Melita, BRKIC, Dejan, VUKOMANOVIC, Predrag
Format: Article
Language:English
Subjects:
Aging
Animals
Ataxia
Biological and medical sciences
Drug dosages
Esterases - metabolism
Humans
Medical sciences
Neurology
Neurons
Neuropathy target esterase
Neurosurgery
Neurotoxicity Syndromes - diagnosis
Neurotoxicity Syndromes - drug therapy
Neurotoxicity Syndromes - etiology
Organophosphate induced delayed polyneuropathy
Organophosphates - toxicity
Organophosphorus
Phosphorylation
Poisoning
Polyneuropathies - chemically induced
Polyneuropathies - diagnosis
Polyneuropathies - drug therapy
Polyneuropathies - enzymology
Studies
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract About 80 years have passed since the first cases of organophosphate induced delayed polyneuropathy (OPIDP), as the consequence of human poisoning with certain organophosphorus compounds, were described in the literature. OPIDP is a relatively rare neurodegenerative disorder in humans characterized by loss of function, ataxia and paralysis of distal parts of sensory and motor axons in peripheral nerves and ascending and descending tracts of spinal cord appearing 2–3 weeks after exposure or later. The molecular target for OPIDP is considered to be an enzyme in the nervous system known as neuropathy target esterase (NTE). This review discusses OPIDP in man with emphasis on clinical presentation, pathogenesis, molecular mechanisms, and possibilities for prevention/therapy.
ISSN:0303-8467
1872-6968
DOI:10.1016/j.clineuro.2010.08.015